Sergi CM. Liver cancer [Internet]. 2021

Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJH, Lim WH, et al. Liver cancer in 2021: global burden of disease study. J Hepatol [Internet]. 2025 Mar 13; Available from: https://doi.org/10.1016/j.jhep.2024.10.031

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin [Internet]. 2025 Jan 16; Available from: http://www.ncbi.nlm.nih.gov/pubmed/39817679

Jaber F, Cholankeril G, El-Serag HB. Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies. J Can Assoc Gastroenterol. 2024;7(5):331–45.

Article  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. 2021 Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3)

Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, et al. 2016 A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Vol. 263, Annals of Surgery.

Kim SS, Lee J, Ahn SB, Chon YE, Yoon E, Jeong SW, et al. 2025 Clinical course and prognosis of long‐term survivors of hepatocellular carcinoma. Aliment PharmacolTher

Carcinoma VA. Hepatocellular. N Engl J Med. 2019;380:1450–62.

Article  Google Scholar 

Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. 2015 Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 21(28)

Shin H, Yu SJ. A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017–2024. Journal of Liver Cancer [Internet]. 2025 Mar 31 [cited 2025 May 19];25(1):19–30. Available from: http://www.e-jlc.org/journal/view.php?number=586

Hernaez R, El-Serag HB. 2018 How we approach it: treatment options for hepatocellular carcinoma red-section. Am J Gastroenterol. 113(6)

Wu X, Lokken RP, Mehta N. 2023 Optimal treatment for small HCC (<3 cm): resection, liver transplantation or locoregional therapy? Vol. 5, JHEP Reports

Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. 2006 A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 243(3)

Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. 2010 A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 252(6)

Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. 2012 A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 57(4)

Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, et al. 2014 Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J GastroenterolHepatol (Australia). 29(1)

Lee HW, Lee JM, Yoon JH, Kim YJ, Park JW, Park SJ, et al. 2018 A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res. 94(2)

Paul SB, Acharya SK, Gamanagatti SR, Sreenivas V, Shalimar S, Gulati MS. Acetic acid versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a randomized controlled trial. Diagn Interv Imaging. 2020;101(2):101–10.

Article  CAS  PubMed  Google Scholar 

ACTRN12621001444875. 2021 A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study). https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12621001444875

Parikh ND, Marshall VD, Green M, Lawrence TS, Razumilava N, Owen D, et al. 2018 Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-medicare. Vol. 62, J Med Imaging RadiatOncol

Kumari R, Sahu MK, Tripathy A, Uthansingh K, Behera M. 2018 Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat Oncol [Internet]. 5(2):HEP08. Available from: https://doi.org/10.2217/hep-2018-0002

Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. HepatOncol. 2020;7(3)

Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, et al. 2022 Economic burden and quality of life of hepatocellular carcinoma in Greater China: a systematic review. 10 Front Public Health

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. 2021 PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Vol. 372, The BMJ

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. 2022 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value in Health. 25(1)

Cayres Mariotti G, Gonçalves Felga GE, Gobbo Garcia R, Mina Falsarella P, Pagnin Schmid B, Tavares Malheiros D, et al. 2024 Cost-effectiveness of radiofrequency ablation versus percutaneous ethanol injection for early hepatocellular carcinoma in a resource-poor setting: a randomized trial. Einstein (16794508). 22

Froelich MF, Schnitzer ML, Rathmann N, Tollens F, Unterrainer M, Rennebaum S, et al. 2021 Cost-effectiveness analysis of local ablation and surgery for liver metastases of oligometastatic colorectal cancer. Cancers (Basel). 13(7)

Jin H, Chalkidou A, Hawkins M, Summers J, Eddy S, Peacock JL, et al. 2021 Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: metastatic liver cancer and hepatocellular carcinoma. Clin Oncol. 33(3)

Jiao XL, Li SC, Hao L, Wang TG, Chen JF. 2022 Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res. 22(2)

Liu B, Wei M, Liu F, Chen S, Peng Z, Li B, et al. 2018 Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis. Am J Transl Res. 10(8)

Spolverato G, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP, et al. 2015 The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg. 39(6)

Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, et al. 2017 Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a Markov modeling study. Radiology. 283(2

Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ. Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases. Int J Radiat Oncol Biol Phys. 2016;95(4):1175–83.

Article  PubMed  Google Scholar 

Liu Q, Zhou S. 2020 Analysis of short-term efficacy and cost-effectiveness of percutaneous radiofrequency ablation and laparoscopic hepatectomy in treatment of small hepatocellular carcinoma. Chinese Journal of General Surgery. 29(5)

McGahan JP, van Raalte VA. History of Ablation. In: vanSonnenberg E, McMullen WN, Solbiati L, Livraghi T, Müeller PR, Silverman SG, Editors. 2005 Tumor ablation: principles and practice [Internet]. New York, NY: Springer New York. 3–16. Available from: https://doi.org/10.1007/0-387-28674-8_1

Zheng E, Yao F. 2024 Real-world management of hepatocellular carcinoma. Navigating the management of hepatocellular carcinoma, an issue of clinics in liver disease: Navigating Manag Hepatocellular Carcinoma An Issue Clin Liver Dis E-Book. 29(1):49–58

Mosadeghrad AM, Jaafaripooyan E, Zamandi M. 2022 Economic evaluation of health interventions: a critical review. Vol. 51, Iranian Journal of Public Health

Xu X, Zhou L, Antwi HA, Chen X. 2018 Evaluation of health resource utilization efficiency in community health centers of Jiangsu Province, China. Hum Resour Health [Internet]. 16(1):13. Available from: https://doi.org/10.1186/s12960-018-0275-y

Shetty SK, Rosen MP, Raptopoulos V, Goldberg SN. 2001 Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms. Journal of Vascular and Interventional Radiology. 12(7)

Cost–effectiveness analysis - Health system efficiency - NCBI Bookshelf [Internet]. [cited 2025 May 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK436886/

Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, et al. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project. Health Technol Assess (Rockv) [Internet]. 2013 [cited 2025 May 19];17(58):1–150. Available from: https://pubmed.ncbi.nlm.nih.gov/24325843/

Terashima T, Higashibeppu Y, Yamashita T, Sakata Y, Azuma M, Munakata H, et al. Comparative analysis of medical costs after hepatectomy versus radiofrequency ablation in patients with hepatocellular carcinoma in real-world clinical practice. Hepatol Res. 2022;52(5).

Mohammadnezhad G, Esmaily H, Talebi M, Jafari M. 2024 Atezolizumab and bevacizumab targeted-therapy in advanced hepatocellular carcinoma: a systematic review of cost-effectiveness analyses. 55 J Gastrointest Cancer

Mohammadnezhad G, Noqani H, Rostamian P, Sattarpour M, Arabloo J. 2023 Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations. 79. Eur J Clin Pharmacol

Loveman E, Jones J, Clegg AJ, Picot J, Colquitt JL, Mendes D, et al. 2014 The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol Assess (Rockv). 18(7)

Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A. 2018 Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Vol. 129 Radiother Oncol

Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, et al. 2018 Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J RadiatOncol Biol Phys. 100(4)

Kron P, Linecker M, Jones RP, Toogood GJ, Clavien PA, Lodge JPA. 2019 Ablation or resection for colorectal liver metastases? A systematic review of the literature. 9 Front Oncol

Hsieh CL, Peng CM, Chen CW, Liu CH, Teng CT, Liu YJ. Benefits and drawbacks of radiofrequency ablation via percutaneous or minimally invasive surgery for treating hepatocellular carcinoma. World J Gastrointest Surg. 2024;16(11):3400.

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Wu Z, Cui D, Shi Y, Zhai B. 2023 Radiofrequency ablation of hepatocellular carcinoma: Current status challenges and prospects. 7 Liver Res

Li D, Kang J, Golas BJ, Yeung VW, Madof DC. 2014 Minimally invasive local therapies for liver cancer. 11 Cancer Biol Med

Margon JF, Chagas AL, Mattos AA, Diniz MA, Gonçalves Felga GE, Boin I de FSF, et al. 2021 O-4 impact of bridge therapy for hepatocellular carcinoma in patients submitted to liver transplantation - Brazilian multicenter study. Ann Hepatol. 24

Wang H, Jin C, Fang L, Sun H, Cheng W, Hu S. 2020 Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review. 18 Cost Eff Resour Allocation

Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. 2015 Liver cancer: approaching a personalized care. 62 J Hepatol

Dou Z, Lu F, Ren L, Song X, Li B, Li X. Efficacy and safety of microwave ablation and radiofrequency ablation in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (United States) [Internet]. 2022 July 29 [cited 2025 May 19];101(30):E29321. Available from: https://journals.lww.com/md-journal/fulltext/2022/07290/efficacy_and_safety_of_microwave_ablation_and.10.aspx